Anika Therapeutics (ANIK) Expected to Release Quarterly Earnings on Friday

Anika Therapeutics (NASDAQ:ANIK) is projected to issue its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to post earnings of $0.42 per share and revenue of $29.44 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:30 AM ET.

Anika Therapeutics Stock Up 0.2%

Anika Therapeutics stock opened at $19.45 on Wednesday. Anika Therapeutics has a 52-week low of $9.01 and a 52-week high of $22.88. The firm’s fifty day moving average is $20.58 and its 200 day moving average is $16.12. The company has a market cap of $260.24 million, a price-to-earnings ratio of 970.50, a PEG ratio of 13.86 and a beta of 0.21.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. Zacks Research downgraded shares of Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, September 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anika Therapeutics in a research report on Monday, September 21st. Barrington Research set a $21.00 price objective on Anika Therapeutics in a research note on Thursday, July 30th. Finally, B. Riley Financial initiated coverage on Anika Therapeutics in a research note on Friday, September 18th. They set a “buy” rating and a $23.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $22.00.

About Anika Therapeutics

Anika Therapeutics, Inc develops, manufactures and commercializes therapeutic products designed to support tissue protection, healing and repair. The company focuses primarily on orthopedics, with products based in part on hyaluronic acid, a naturally occurring substance found in connective tissue and joint fluid.

Anika’s orthopedic portfolio includes Monovisc and Orthovisc, viscosupplementation products used to help relieve pain associated with osteoarthritis of the knee, as well as Cingal, which combines hyaluronic acid with a corticosteroid.